Your Messages Inbox
Your Article Summary
See Latest ArticlesBoehringer Ingelheim maintains its growth path in 2008, again growing faster than the pharmaceutical market - major investments once again in Research and Development - good outlook for further growth in 2009
Boehringer Ingelheim, 04/22/09
Boehringer Ingelheim maintained its growth path in 2008 too, thereby meeting the goals it had set itself. As the company announced at its Annual Press Conference in Ingelheim, the corporation's net sales rose to €11.6 billion. This corresponds to a currency-adjusted increase of +9.5% and +5.9% on a euro-basis. Boehringer Ingelheim thus showed stronger growth than the world pharmaceutical market for the ninth year in a row.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Visanne cleared for market launch in Europe as new treatment option for endometriosis
BayNews International, 12/08/09
Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
Bristol Myers-Squibb Company, 12/07/09
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
MabThera/Rituxan is the first treatment to show improved overall survival in previously untreated patients with chronic lymphocytic leukemia
Roche, 12/09/09
Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation
PhRMA, 12/09/09
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Cell Therapeutics, 12/08/09
Article Search
Sponsor